Market Place
Sourcing Support
Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules
06 Nov 2024 //
FIERCE BIOTECH
Tango Therapeutics Reports Positive TNG462 Data & PRMT5 Update
06 Nov 2024 //
BUSINESSWIRE
Tango Therapeutics Reports Q3 2024 Results & Business Highlights
06 Nov 2024 //
BUSINESSWIRE
Tango Therapeutics to Participate in Upcoming Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Tango Therapeutics Reports Q2 2024 Results And Business Highlights
07 Aug 2024 //
BUSINESSWIRE
Tango Therapeutics: Presenting At Goldman Sachs Healthcare Event
05 Jun 2024 //
BUSINESSWIRE
Medivir Tng348 Program Discontinued: By Licensee Tango Therapeutics
23 May 2024 //
PR NEWSWIRE
Tango Therapeutics Announces Discontinuation of TNG348 Program
23 May 2024 //
BUSINESSWIRE
Bicycle’s $555M placement; Tango Therapeutics scraps cancer program
23 May 2024 //
ENDPTS
Tango Stops Early Cancer Trial Liver Toxicity, Drops Out of Race Against Roche
23 May 2024 //
BIOSPACE
Tango Therapeutics: Q1 2024 Financials, Business Highlights
08 May 2024 //
BUSINESSWIRE
Tango Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2024 //
BUSINESSWIRE
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
18 Mar 2024 //
BUSINESSWIRE
Tango Therapeutics to Participate in Upcoming Investor Conferences
06 Mar 2024 //
BUSINESSWIRE
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline
05 Mar 2024 //
GLOBENEWSWIRE
Tango Therapeutics to Present at 6th Annual Biotechnology Conference
31 Jan 2024 //
GLOBENEWSWIRE
Tango Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
GLOBENEWSWIRE
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348
04 Jan 2024 //
PR NEWSWIRE
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348
03 Jan 2024 //
GLOBENEWSWIRE
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors
13 Nov 2023 //
GLOBENEWSWIRE
Tango Therapeutics Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Tango Therapeutics to Present at the Jefferies London Healthcare Conference
07 Nov 2023 //
GLOBENEWSWIRE
Tango Therapeutics To Highlight Data On Precision Oncology Pipeline
18 Sep 2023 //
PRESS RELEASE
Tango Therapeutics Announces FDA Clearance of IND Application for TNG348
06 Sep 2023 //
GLOBENEWSWIRE
Tango To Participate In H.C. Wainwright 25Th Annual Global Investment Conference
05 Sep 2023 //
PRESS RELEASE
Tango Therapeutics Announces Updates to Its Board of Directors
29 Aug 2023 //
GLOBENEWSWIRE
Tango Therapeutics Announces $80 million Private Placement Financing
10 Aug 2023 //
GLOBENEWSWIRE
Tango Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial
24 Jul 2023 //
GLOBENEWSWIRE
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial
10 Jul 2023 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Tango Therapeutics Reports1Q 2023 FYR and Provides Business Highlights
09 May 2023 //
GLOBENEWSWIRE
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs
18 Apr 2023 //
GLOBENEWSWIRE
Tango Announces FDA Clearance of Investigational New Drug Application for TNG260
03 Apr 2023 //
GLOBENEWSWIRE
Tango Reports Fourth Quarter and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs
14 Mar 2023 //
GLOBENEWSWIRE
Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank
10 Mar 2023 //
GLOBENEWSWIRE
Tango Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2023 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in Upcoming Investor Conferences
01 Mar 2023 //
GLOBENEWSWIRE
Tango Therapeutics Appoints Adam Crystal as President of R&D
28 Feb 2023 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in Upcoming Investor Conferences
02 Feb 2023 //
GLOBENEWSWIRE
Tango Therapeutics Announces FDA Clearance of Investigational NDA for TNG462
25 Jan 2023 //
GLOBENEWSWIRE
Tango Therapeutics Reports 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in Upcoming Investor Conferences
07 Nov 2022 //
GLOBENEWSWIRE
Tango Announces Presentation of Data on PRMT5 Inhibitors TNG908 and TNG462
19 Oct 2022 //
GLOBENEWSWIRE
Tango Therapeutics Announces Presentation of Preclinical Data on TNG260
05 Oct 2022 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Tango Therapeutics Reports Q2 Financial Results and Provides Business Highlights
10 Aug 2022 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in the 13th Annual Wedbush Conference
02 Aug 2022 //
GLOBENEWSWIRE
Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
27 Jun 2022 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in Goldman Sachs Healthcare Conference
08 Jun 2022 //
GLOBENEWSWIRE
Tango Therapeutics Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022
09 May 2022 //
GLOBENEWSWIRE
Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
Tango Tx says Presentation of PC Data on TNG908 at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Tango Tx Presents TNG908 Preclinical Combination Data at 2022 ESMO
03 Mar 2022 //
GLOBENEWSWIRE
Tango Tx to Participate in Upcoming Investor Conferences
28 Feb 2022 //
GLOBENEWSWIRE
FDA Clears Tango`s TNG908 IND and Recent Pipeline Progress Updates
24 Jan 2022 //
GLOBENEWSWIRE
Tango Therapeutics Announces Presentation of Data at AACR-NCI-EORTC 2021
30 Sep 2021 //
BUSINESSWIRE
TANGO Analysis Supports the Potency, Durability of Dolutegravir Plus Lamivudine
20 Jul 2021 //
FIRSTWORDPHARMA
